New injection for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new drug called TQB2934 for patients whose multiple myeloma (a blood cancer) has returned or stopped responding to previous treatments. The goal is to see if this injection can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma that has come back after treatment or is not responding to your current treatment
- Your cancer is measurable on imaging or lab tests
- You are between 18 and 75 years old and in good enough health to tolerate treatment (ECOG score 0–2)
- You have not had certain recent treatments: CAR-T or CAR-NK therapy within 3 months, stem cell transplant within 3–6 months, chemotherapy or targeted drugs within 2–3 weeks, or proteasome inhibitors within 2 weeks
- Your organ function (liver, kidneys, heart) is adequate based on blood and imaging tests
- If you can have children, you agree to use reliable birth control during the study and for 12 months after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This trial tests a new injectable drug, TQB2029, for people with multiple myeloma. It aims to see if the drug is safe and effective, and may be an option if you have measurable disease and are in relatively good health.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This Phase 2 trial studies a treatment called SVRd in people newly diagnosed with multiple myeloma that has spread to areas outside the bone (called extramedullary disease). It aims to see how well the treatment works and whether it is safe for this specific group.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.